Navigation Links
Stem Cell Treatment Leader Tiantan Puhua Adds Experienced International Medical Staff for Expanding Numbers of Patients

BEIJING, Jan. 7 /PRNewswire/ -- Tiantan Puhua Hospital Stem Cells Center (, the worldwide leader in using stem cells to effectively treat neurological disorders, announced today six new globally experienced additions to its medical and research staff that significantly expand the hospital's treatment capabilities for growing numbers of incoming international patients. The six senior doctors include the distinguished Dr. Jiang Ping, who was named Chief Scientific Advisor of Tiantan Puhua. Dr. Jiang lectured at and received his postgraduate degree from Harvard Medical School in 1997. He also worked for several years in the Department of Tumor Therapy at Massachusetts General Hospital, and is currently Director at the Laboratory of Stem Cell and Genetic Engineering at the Wistar Institute of the University of Pennsylvania. As well, Tiantan Puhua named Dr. Zhou Jingli, a recent visiting scholar at Michigan State University, as Chief Neurologist in Beijing. Dr. Zhou is joined by neurologists Dr. Li Miaomiao, who has treated dozens of international patients in China, and Dr. Song Changua. Dr. Song, who recently returned from a research stint at Japan's Kansai Medical University, where he received his Ph.D., has published his stem cell research in Western scientific journals such as "Immunobiology." Renowned Chinese neurosurgeons Dr. Han Jiebing and Dr. Yu Yong, both of whom have published research findings in Chinese medical journals, joined Tiantan Puhua's experienced medical team to deepen the hospital's stem cell treatment capabilities. Dr. Yu also recently returned to China after earning a degree at Japan's Nagoya City University Medical School where he worked at the university's Medical School Hospital, bringing back a wealth of experience in using stem cells for clinical applications.

Dr. Sherwood Yang, Vice President of Tiantan Puhua Hospital, said, "We are proud to be adding the world's most skilled medical professionals to our team to treat the increasing numbers of those suffering from neurological illnesses worldwide, but restricted from receiving treatment in their own countries." Dr. Yang continued, "I am confident that our ever-improving treatment programs, experienced doctors, outstanding support personnel, and stringent scientific protocols represent top quality in stem cell treatment, and are things not easily replicated."

About Tiantan Puhua Neurosurgical Hospital

Tiantan (Temple of Heaven) Puhua Neurosurgical Hospital, a Hospital under TP Biomedical Ltd., is a world-class neurological treatment facility in Beijing that is gaining renown as the world's foremost center for treatment of Parkinson's disease, brain injury, Cerebral palsy, Batten disease, and a range of other neurological disorders through its groundbreaking stem cell therapy. The Hospital collaborates with the Stem Cells Research Center of Peking University, which is the foremost stem cells research center in China. There, stem cells are cultured for clinical application. To date, Tiantan Puhua Hospital has treated with stem cells over 150 international patients suffering from a range of neurological disorders. More details about Tiantan Puhua Hospital can be found on the website

    For inquiries, please contact:

    Vivian Wang - International Department
    Tel: +86 10 67035566 ext. 526
    Tiantan Puhua Neurosurgical Hospital
    Tiantan Nanli, Beijing 100050, CHINA

More information can also be found on China's leading stem cells news site:

This release was issued through eReleases(TM). For more information, visit

SOURCE Tiantan Puhua Neurosurgical Hospital
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Circassia Completes Patient Recruitment for Phase II Clinical Trial of Toleromune(R) Allergy Treatment
2. MRI Emerges As Vital Resource in Treatment of Back Pain
3. Arena Pharmaceuticals Announces Preliminary Results of Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
4. Three Studies Presented at the American Society of Hematology Annual Meeting Showed Response to Treatment with Campath(R) in Patients with High-Risk CLL
5. Novel Therapeutic Approaches May Transform Treatment and Improve Patient Outcomes in Several Platelet Disorders
6. VentiRx Pharmaceuticals Commences Phase I Clinical Trial of VTX-2337, a Novel TLR8 Agonist for the Treatment of Oncology
7. S*BIO Advances JAK2 Inhibitor SB1518 into Phase 1/2 Clinical Trial in Australia for the Treatment of Chronic Idiopathic Myelofibrosis
8. Light Sciences Oncology Completes Patient Enrollment in Phase 3 Clinical Trial of Litx as a Treatment for Hepatocellular Carcinoma
9. Arthritis Advisory Committee Recommends FDA Approval of Febuxostat for the Treatment of Hyperuricemia in Patients With Gout
10. Medarex Announces Initiation of Phase 1b Clinical Development Program with MDX-1106 for the Treatment of Cancer
11. New Cancer Treatment Shrinks Pancreatic Tumor
Post Your Comments:
(Date:12/1/2015)... 01, 2015 ... the "Medium Molecular Weight Polyisobutylene Market ... Other Applications - Global Industry Analysis, Size, ... 2023" report to their offering. ... addition of the "Medium Molecular Weight ...
(Date:12/1/2015)... CLEVELAND , Dec. 1, 2015   ... innovation firm, today announced the publication of a ... Entering the Direct-to-Consumer Medical Market". The whitepaper gives ... roadmap for successfully penetrating this lucrative segment. ... purchase healthcare products to manage their own health, ...
(Date:12/1/2015)... 1, 2015 Array BioPharma Inc. ... its Chief Executive Officer, Ron Squarer ... Healthcare Conference in New York.  The public ... through a webcast on the Array BioPharma ... --> , ...
Breaking Medicine Technology:
(Date:12/1/2015)... (PRWEB) , ... December 02, 2015 , ... ... research “ Gastrointestinal events and association with initiation of treatment for osteoporosis ”. ... the use of pharmacological treatment in patients diagnosed with osteoporosis. Based on a ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... its acquisition by Jordan Industries International, LLC (“JII”). , With support from JII, ... and maintenance services to hospitals, surgery centers, clinics, research labs and medical facilities ...
(Date:12/1/2015)... ... , ... According to an article published on November 16th by ... U.S. Department of Health and Human Services, claiming that any states which do not ... clause in the law prohibiting the denial of coverage for pre-existing conditions. The article ...
(Date:12/1/2015)... ... December 01, 2015 , ... Baptist Medical Center Jacksonville ... is the only hospital in the region providing what is known as the ... pacing patients were revealed recently at a medical conference and published in The ...
(Date:12/1/2015)... ... December 01, 2015 , ... Dr. Paul Vitenas, one of ... has been named by MedEsthetics magazine as the Best Single Physician Practice in the ... the many elite aesthetic physicians honored by the industry publication. , Dr. Vitenas ...
Breaking Medicine News(10 mins):